Bio Job Blog : Bio Jobs : Biotechnology Jobs : Biopharmaceutical Jobs : Bioscience, Biotech Jobs : Bio Job Blog : Biocareer : Bio-Business Training, Biotechnology Training : Jobs in Biology : Internships in Biology : Internships in Biotechnology

Over the past year or so, more graduate students and postdoctoral fellows have been asking me about management consulting careers in the life sciences. I spent several years working as an independent management consultant and while it was a great experience the revenue stream was unreliable at best and the ability to work was highly contingent upon the economy. However, I can assure that my experiences as an independent management consultant were marketing different than those of consultants who work at the consulting firms like McKinsey or the Boston Consulting Group. For those of you interested in life style of a high-powered management consultant I highly recommend you visit their websites for more info. 

I invited Susan Colilla, PhD, MPH, President of the consulting firm Integrative Epidemiology LLC describe her experiences about becoming a life sciences consultant so that BioJobBlog job readers (who may be considering this as a career option), might get an idea and appreciate what it takes to get into and be successful in this line of work.

My Life as a Life Sciences Management Consultant

by Susan Colilla

After doing a second postdoc at University of Pennsylvania as an Instructor (nebulous junior non-faculty type position) and becoming frustrated with all the extensive work requirements for a tenure-track position, I started searching for a job in pharmaceutical industry.

While searching for a position, a potential employer, who didn’t have an opening at the time, asked if I would be interested in consulting.  As I was interested in this area, I started consulting for industry and realized that I enjoyed working on different projects in epidemiology and genetics, and loved that I could work from my home office and give up a commute. 

The flexibility in consulting is great.  I plan the work around my schedule, and the pay has been rewarding as well.  Last year, I formally incorporated my business, Integrative Epidemiology, LLC.  I offer services in literature reviews, study planning/design, data analysis and grant or manuscript writing in the areas of human genetics or epidemiology. 

As I build my business, I have learned about how to run a business, bookkeeping/billing, taxes, legal issues/contracts, and marketing.  Moving from academia to pharma/industry is tricky unless you have connections with those who hire in the industry.  One of the biggest challenges for me as a self-employed consultant is dedicating a good proportion of my time to networking with others and marketing my services, rather than doing science-related work.  It helps that I am very social by nature and enjoy meeting new people.

 I am also fortunate to be married to someone who makes a good income and receives benefits as this helps support our family.  There can be a sporadic flow of income with consulting, especially during a recession and new business slows down.  I have also partnered up with another consulting group (Venebio, LLC, based in Richmond, VA) to expand the pool of potential clients and work with a group of scientists to offer a broader range of services. 

For those of you who want to learn more about getting into the consultant business, Susan highly recommends an article that recently appeared in the Scientist. She shared with me that the article offers a great list of things to consider before starting a consultancy and that she “wished that she had seen it a couple years ago when I started out in this business!”

Until next time...

Good Luck and Good Job Hunting!!!!  

• Email This
• Print
• Trackbacks
• Share Link

By now, I think that most BioJobBlog readers understand that the job market for life scientists is lousy and that it isn’t likely to improve anytime soon. I know that many of you have spent close to 10 years training for a shot at an R&D job but the reality is that everybody needs to work to put food on the table—whether or not you find a job in your chosen profession. To that end, now may be a good time for those of you who are finding it difficult to land a job to consider one more year of training to get a certificate in a field that keeps you in science but not in R&D.

I came across interesting post today at the Resume Bear blog that discussed 10 certificate programs that can help people transition to new careers to find jobs. Interestingly, four of the programs are good fits for life scientists who are willing modify their careers to be gainfully employed. They are:

Clinical Trials Design and Management

“Pharmaceutical drug and medical device development is one of the premier industries of the 21st century, and the success of this vital industry depends upon the complex process of studying new products to verify their effectiveness and safety.”

Regulatory Affairs

“Professionals are needed to guide drug development and medical device companies through FDA imposed regulation issues pertinent to the pharmaceutical and biological industry.”

Project Management

“As project cycles get shorter – and budgets get leaner – project managers are vital to the success of organizations today.”

Copyediting

“Bridging the gap between writers and publishers – especially technical and nonfiction copyediting – is one of today’s most marketable skills for both full-time and freelance work.”

Another one that was not on the list biotechnology certificate programs in which students learn about product development, regulatory affairs and best business practices in the life sciences industry.

Not surprisingly, many certificate programs are offered at local community colleges and frequently online. For regulatory affairs training you might try the Drug Information Association and Regulatory Affairs Professionals Society. The Project Management Institute offers training in project management and the Editorial Freelancers Association offers its members courses in copyediting. Mercer County College in West Windsor NJ in association with a local clinical research organization developed a “hands-on” certificate program in clinical trials design and management. 

In my opinion, certificate programs are worth checking out. They are designed for working professionals (courses are typically given in the evenings and weekends); usually only take 12 months to complete (what is one more year in the scheme of things) and improves the likelihood of finding a job because you now have a marketable skill set! It certainly beats collecting unemployment or sleeping in your old bed at your parent’s home—or not?

Hat tip to Resume Bear

Until next time...

• Email This
• Print
• Comments (2)
• Trackbacks
• Share Link

Roche announced Tuesday that it will replace Arthur Levinson, PhD, Genentech’s current CEO and American biotechnology pioneer, with Pacal Soriot, DVM, MBA who currently leads Roche’s worldwide commercial operations.  Dr. Levinson will become Chairman of Genentech’s newly configured board of directors but no longer have control over day-to-day operations at the company.  Mr. Soriot will become CEO of Genentech and head all of Roche’s pharmaceutical activities in the US. Some of the other changes that will occur at the company include: Susan Desmond-Hellmann, Genentech’s president of product development, will move into an advisory role after the middle of this year. Genentech CFO David Ebersman is leaving the company and Ian Clark, who heads commercial operations for Genentech, will be chief marketing officer of Roche’s pharma division.

Dr. Levinson and Mr. Soriot will lead the efforts to combine all of Roche’s North American operations which ultimately will be run from Genentech’s South San Francisco location. Many of the activities at Roche’s previous North American headquarters in Nutley, NJ will move west, which means downsizing, more layoffs and possible closure of the Nutley site. 

Dr. Levinson, one of Genentech’s early employees, joined the company as a senior scientist in 1980 and has been its chief executive since 1995. During his tenure, Genentech became the largest, most profitable and perhaps the most innovative biotechnology company in the US. Unlike Dr. Levinson, who is a molecular biologist and has over 30 years of experience in developing successful protein-based drugs, Dr. Soriot, a former Sanofi-Aventis financial and commercial operations executive has little or no experience with biotechnology products.

With this in mind, I suspect that many things will change at Genentech as Roche attempts to transform the once heralded biotechnology company into a subsidiary of its pharmaceutical division. Don’t be surprised if you see a mass exodus from company. Farewell DNA, all good things must end!

Until next time...


Good Luck and Good Job Hunting (try Genentech, there will be openings soon)
 

• Email This
• Print
• Comments (1)
• Trackbacks
• Share Link

While I have never been layed off, I understand how awful and painful it must be. After all, unlike people who were fired for cause or otherwise, most people who are layed off are performing well but they simply became too expensive or expendable to remain with a company facing financial exigency.

Most of us feel for employees who have been layed off—anyone who has experienced a layoff will tell you that it can be a life altering or changing event. But, what about the people who are charged with delivering the bad news to the employees who will be layed off? How do you think they feel and what impact does it have on their lives? 

There was a poignant and heartfelt piece in this past Sunday’s New York Times that was written by a company executive who made the decision to layoff workers and then delivered the news to them himself. While his plight doesn’t compare with that of the employees who lost their jobs, it shows how difficult and disruptive layoffs can for companies that are forced to downsize.

Until next time…

Good Luck and Good Job Hunting!!!!!!

• Email This
• Print
• Trackbacks
• Share Link

I had many discussions with undergraduate students at the ABRCMS in Orlando last week who were interested in pursuing PhD degrees in the biomedical sciences. I felt that I had an ethical and moral responsibility as a former academic and career development professional to tell them that the job market for PhDs is not good and that it is likely to get worse over the next few years. These discussions prompted me to revisit the role and contributions of tenure to the lack of academic jobs in the US today.

As I stated in a previous post, systemic changes must be made to the current academic paradigm to increase the likelihood that PhDs will be able to find jobs at the end of their training. In that post, I suggested that abolishing tenure and replacing it with renewable, performance-based five year contracts may help to reduce the glut of jobless PhDs by freeing up a small percentage of new faculty positions every five years. While this approach has been tried at several academic institutions, it has been largely been deemed unsuccessful. That said, I came across a provocative article in today’s New York Times about a bold new tenure proposal put forth by Michelle Rhee, the new, 38-year old Chancellor of the Washington, DC school system.

Ms Rhee’s revolutionary proposal offers tenured teachers salaries raises of up to $40,000 per year to give up tenure. It is important to note she has not proposed to completely abolish tenure. Under her proposal, teachers would choose between two compensation options—the green or red plans. Salaries for teachers in the green plan would rise meteorically, nearly doubling by 2010, but they would have to give up tenure for one year, after which they would need a principal’s recommendation to keep their job or face dismissal. Teachers who choose the red plan would also get big pay raises but would lose seniority rights that allow them to bump more junior teachers if their school closes or is overhauled. Red plan teachers who are not hired by other schools would either have to take early retirement, a buyout or face eventual dismissal. I like her plan because poorly- or under performing teachers can opt to take the cash and then either drastically improve to keep their higher paying jobs or do nothing, get paid well for a year or two and then get fired.

While Ms. Rhee’s proposal may work at the primary and secondary school levels, it likely would not be effective at the college and postgraduate levels, where salaries vary widely and are largely grant driven. Instead, I propose that tenure-for-life should remain intact at these institutions but be replaced with a “for cause” tenure review system. This system is tried and true and similar models have been successfully used for over 100 years by employers and labor unions. In this model, management and its unions agree upon the job responsibilities and performance metrics for individual that must be met each year, e.g. an annual performance review.  If a person is under performing or fails to meet his/her performance metrics, an employer can attempt to dismiss the employee “for cause” reasons.  However, before a dismissal for cause can occur, the employer must convince a judge or arbitrator in a hearing that the employee in question has violated the “dismissal for cause” provisions.  Because an employer must prove that an employee has violated the provisions that constitute for cause dismissal, the “for cause” claims against individual employees must be fastidiously documented and vigorously substantiated. This prevents employers from arbitrarily firing employees who are either outspoken troublesome or disruptive. According to my wife, who has been a union-side labor lawyer and union representative for 20 year, this system works well because the players (management and unions) all understand, abide by and play according to the rules of the game.

So what are some of the performance-based “for cause” metrics that I think ought to be considered for yearly evaluations of tenured professors? They are not much different than those currently used to adjudicate tenure decisions. That said, I propose the following five categories: 1) teaching, 2) publication record, 3) grant support, 4) institutional service and 5) commitment to innovation. In my opinion, adoption of the “for cause” tenure review model would help to do two things: improve the overall performance of tenured faculty members and provide newly minted PhDs and postdoctoral fellows with regularly occurring new job opportunities.

Until next time…

Good Luck and Good Job Hunting!!!!!!!!

• Email This
• Print
• Comments (2)
• Trackbacks
• Share Link